O Shaughnessy Asset Management LLC Boosts Stock Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

O Shaughnessy Asset Management LLC increased its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 260.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 248,844 shares of the company’s stock after acquiring an additional 179,866 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $3,929,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. raised its position in Dr. Reddy’s Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the period. Aikya Investment Management Ltd lifted its stake in Dr. Reddy’s Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after buying an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Dr. Reddy’s Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after buying an additional 3,911,404 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Dr. Reddy’s Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company’s stock worth $44,444,000 after buying an additional 2,313,987 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock valued at $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analyst Ratings Changes

RDY has been the topic of a number of research analyst reports. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Up 0.7 %

RDY opened at $13.25 on Thursday. The firm has a market capitalization of $11.06 billion, a price-to-earnings ratio of 21.10 and a beta of 0.48. The company’s 50 day simple moving average is $13.38 and its two-hundred day simple moving average is $14.55. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.50 and a 1-year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.